<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214081</url>
  </required_header>
  <id_info>
    <org_study_id>Vonoprazan-5003</org_study_id>
    <secondary_id>JapicCTI-163202</secondary_id>
    <nct_id>NCT03214081</nct_id>
  </id_info>
  <brief_title>Special Drug Use Surveillance of Takecab for &quot;Maintenance Therapy of Reflux Esophagitis: Long-term Use&quot;</brief_title>
  <official_title>Special Drug Use Surveillance of Takecab Tablets for &quot;Maintenance Therapy of Reflux Esophagitis: Long-term Use&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of long-term administration
      of Vonoprazan tablets (Takecab tablets) when used as maintenance therapy for reflux
      esophagitis in routine clinical settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called Vonoprazan (Takecab). Vonoprazan is being
      tested to treat people who have reflux esophagitis.

      This study will look at the safety and efficacy of long-term administration of Vonoprazan
      tablets (Takecab tablets) when used as maintenance therapy for reflux esophagitis in routine
      clinical settings.

      The study will enroll approximately 1000 patients.

      â€¢ Vonoprazan 10 mg/20 mg

      This multi-center trial will be conducted in Japan.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who had one or more adverse drug reactions</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Adverse drug reaction refers to adverse events related to administered drug. Time frame is defined the duration from the start of treatment with Vonoprazan tablets (Takecab) as maintenance therapy up to 12 months after the start of treatment (or at the time of treatment discontinuation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic relapse rates</measure>
    <time_frame>At the end of treatment (up to 12 months)</time_frame>
    <description>Endoscopic relapse rates (percentages of patients meeting the criteria of Grade A to D according to the Los Angeles classification) will be tabulated in patients for whom endoscopic findings at the start of treatment with Vonoprazan tablets (Takecab), during treatment, and 12 months after the start of treatment (or at the time of treatment discontinuation) administered as maintenance therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in number of participants with the severity of subjective symptoms</measure>
    <time_frame>At the start of treatment (Week 0) and the end of treatment (up to 12 months)</time_frame>
    <description>Changes in number of participants with the severity of subjective symptoms will be tabulated in patients for whom the severity of subjective symptoms at the start of treatment with Vonoprazan tablets (Takecab), and at each observation time point after treatment administered as maintenance therapy.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1237</enrollment>
  <condition>Reflux Esophagitis</condition>
  <arm_group>
    <arm_group_label>Vonoprazan 10 mg/20 mg</arm_group_label>
    <description>The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily; however, if the efficacy is inadequate, the dosage may be increased up to 20 mg once daily. Participants will receive interventions as part of routine medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Vonoprazan tablets</description>
    <arm_group_label>Vonoprazan 10 mg/20 mg</arm_group_label>
    <other_name>Takecab tablets</other_name>
    <other_name>TAK-438</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of participants with a diagnosis of reflux esophagitis
        and received dose of Takecab/Vonoprazan in the routine medical care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who require maintenance therapy for relapsed/recurrent reflux esophagitis

        Exclusion Criteria:

          -  Participants meeting the criteria of grade A to D according to the Los Angeles
             classification (Hoshihara's modification), by means of endoscopy at the initiation of
             maintenance therapy with Takecab tablets

          -  Participants with a previous history of hypersensitivity to ingredients in Takecab
             tablets

          -  Participants taking atazanavir sulfate or rilpivirine hydrochloride
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Takeda Selected Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2017</study_first_submitted>
  <study_first_submitted_qc>July 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

